磁共振新技术评价帕金森病治疗效果的应用价值(5)
[19]BLACK K J， KOLLER J M， CAMPBELL M C， et al. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease [J].The Journal of neuroscience ： the official journal of the Society for Neuroscience，2010，30(48)：16284-16292.
[20]STEWART S B， KOLLER J M， CAMPBELL M C， et al. Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI [J]. PeerJ， 2014， 2(e687).
, http://www.100md.com
[21]ELLIS C M， LEMMENS G， WILLIAMS S C， et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease： a proton magnetic resonance spectroscopy study [J]. Neurology， 1997， 49(2)： 438-444.
[22]BAGGA P， CHUGANI A N， VARADARAJAN K S， et al. In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease： recovery of cerebral metabolism with acute levodopa treatment [J]. Journal of neurochemistry， 2013， 127(3)： 365-377.
, http://www.100md.com
[23]CIURLEO R， BONANNO L， DI LORENZO G， et al. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy： A proton magnetic resonance spectroscopy study [J]. Neuroscience letters， 2015， 599：55-60.
[24]MELON C， CHASSAIN C， BIELICKI G， et al. Progressive brain metabolic changes under deep brain stimulation of subthalamic nucleus in parkinsonian rats [J]. Journal of neurochemistry， 2015， 132(6)： 703-712.
[25]LLUMIGUANO C， KOVACS N， USPRUNG Z， et al. 1H-MRS experiences after bilateral DBS of the STN in Parkinson's disease [J]. Parkinsonism & related disorders， 2008， 14(3)： 229-232.
, http://www.100md.com
[26]BAIK H M， CHOE B Y， SON B C， et al. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy [J]. European journal of radiology， 2003， 47(3)： 179-187.
[27]ULLA M， BONNY J M， OUCHCHANE L， et al. Is R2* a new MRI biomarker for the progression of Parkinson's disease？ A longitudinal follow-up [J]. PloS one， 2013， 8(3)： e57904.
[28]DEVOS D， MOREAU C， DEVEDJIAN J C， et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease [J]. Antioxidants & redox signaling， 2014， 21(2)： 195-210.
, http://www.100md.com
[29]VAILLANCOURT D E， SPRAKER M B， PRODOEHL J， et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease [J]. Neurology， 2009， 72(16)： 1378-1384.
[30]陈燕生，方元，史文宗，等. 早期帕金森病黑质致密部FA值量化研究[J]. 放射学实践，2014，04：387-389.
[31]PERAN P， CHERUBINI A， ASSOGNA F， et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature [J]. Brain ： a journal of neurology， 2010， 133(11)： 3423-3433.
[32]YOO H B， LEE J Y， LEE J S， et al. Whole-brain diffusion-tensor changes in parkinsonian patients with impulse control disorders [J]. Journal of clinical neurology， 2015， 11(1)： 42-47.
编辑/金昊天, 百拇医药(董艳超 刘兰祥)
[20]STEWART S B， KOLLER J M， CAMPBELL M C， et al. Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI [J]. PeerJ， 2014， 2(e687).
, http://www.100md.com
[21]ELLIS C M， LEMMENS G， WILLIAMS S C， et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease： a proton magnetic resonance spectroscopy study [J]. Neurology， 1997， 49(2)： 438-444.
[22]BAGGA P， CHUGANI A N， VARADARAJAN K S， et al. In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease： recovery of cerebral metabolism with acute levodopa treatment [J]. Journal of neurochemistry， 2013， 127(3)： 365-377.
, http://www.100md.com
[23]CIURLEO R， BONANNO L， DI LORENZO G， et al. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy： A proton magnetic resonance spectroscopy study [J]. Neuroscience letters， 2015， 599：55-60.
[24]MELON C， CHASSAIN C， BIELICKI G， et al. Progressive brain metabolic changes under deep brain stimulation of subthalamic nucleus in parkinsonian rats [J]. Journal of neurochemistry， 2015， 132(6)： 703-712.
[25]LLUMIGUANO C， KOVACS N， USPRUNG Z， et al. 1H-MRS experiences after bilateral DBS of the STN in Parkinson's disease [J]. Parkinsonism & related disorders， 2008， 14(3)： 229-232.
, http://www.100md.com
[26]BAIK H M， CHOE B Y， SON B C， et al. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy [J]. European journal of radiology， 2003， 47(3)： 179-187.
[27]ULLA M， BONNY J M， OUCHCHANE L， et al. Is R2* a new MRI biomarker for the progression of Parkinson's disease？ A longitudinal follow-up [J]. PloS one， 2013， 8(3)： e57904.
[28]DEVOS D， MOREAU C， DEVEDJIAN J C， et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease [J]. Antioxidants & redox signaling， 2014， 21(2)： 195-210.
, http://www.100md.com
[29]VAILLANCOURT D E， SPRAKER M B， PRODOEHL J， et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease [J]. Neurology， 2009， 72(16)： 1378-1384.
[30]陈燕生，方元，史文宗，等. 早期帕金森病黑质致密部FA值量化研究[J]. 放射学实践，2014，04：387-389.
[31]PERAN P， CHERUBINI A， ASSOGNA F， et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature [J]. Brain ： a journal of neurology， 2010， 133(11)： 3423-3433.
[32]YOO H B， LEE J Y， LEE J S， et al. Whole-brain diffusion-tensor changes in parkinsonian patients with impulse control disorders [J]. Journal of clinical neurology， 2015， 11(1)： 42-47.
编辑/金昊天, 百拇医药(董艳超 刘兰祥)